Filings
| Filing | Date | Type | Filed with |
|---|
| LEQEMBI Pen (Subcutaneous Formulation of LEQEMBI) Now Available in Japan for Patients with Early Alzheimer’s Disease | Nov 12, 2026 | Operations update | Tokyo Stock Exchange |
|---|
| CONSOLIDATED FINANCIAL REPORT [IFRS] for the Six-Month Period Ended September 30, 2026 | Nov 10, 2026 | Other filings | Tokyo Stock Exchange |
|---|
| Financial Results for the Six-Month Period Ended September 30,2026 Reference Data | Nov 10, 2026 | Results | Tokyo Stock Exchange |
|---|
| Revenue of LEQEMBI (Preliminary Basis) | Oct 28, 2026 | Other filings | Tokyo Stock Exchange |
|---|
| Notification Regarding Receipt of Dividend from a Consolidated Subsidiary | Oct 2, 2026 | Dividend | Tokyo Stock Exchange |
|---|
| LEQEMBI (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China | Sep 3, 2026 | Other filings | Tokyo Stock Exchange |
|---|
| CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2026 | Aug 3, 2026 | Other filings | Tokyo Stock Exchange |
|---|
| Revenue of LEQEMBI (Preliminary Basis) | Jul 29, 2026 | Results | Tokyo Stock Exchange |
|---|
| FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease | Jul 13, 2026 | Other filings | Tokyo Stock Exchange |
|---|
| Notification Regarding Issuance of Unsecured Straight Bonds | Jun 3, 2026 | Financing | Tokyo Stock Exchange |
|---|